Cargando…

Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse

BACKGROUND AND HYPOTHESIS: Throughout the life stages of women with schizophrenia-spectrum disorders (SSD), lower estrogen levels are associated with more severe disease course. At perimenopause in the mid-forties, estrogen levels decline to remain persistently low after menopause. This period is hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommer, Iris E, Brand, Bodyl A, Gangadin, Shiral, Tanskanen, Antti, Tiihonen, Jari, Taipale, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810004/ https://www.ncbi.nlm.nih.gov/pubmed/36198044 http://dx.doi.org/10.1093/schbul/sbac139

Ejemplares similares

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2020)

The clinical course of schizophrenia in women and men—a nation-wide cohort study
por: Sommer, Iris E., et al.
Publicado: (2020)

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis
por: Hamina, Aleksi, et al.
Publicado: (2020)

Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
por: Lintunen, Jonne, et al.
Publicado: (2021)

Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
por: Lintunen, Jonne, et al.
Publicado: (2021)

S210. COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS FOR RISK OF ATTEMPTED OR COMPLETED SUICIDE AMONG PERSONS WITH SCHIZOPHRENIA
por: Taipale, Heidi, et al.
Publicado: (2020)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
por: Holm, Minna, et al.
Publicado: (2020)

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
por: Puranen, Arto, et al.
Publicado: (2023)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
por: Tiihonen, Miia, et al.
Publicado: (2016)

Morbidity and mortality in schizophrenia with comorbid substance use disorders
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Association between gut permeability, brain volume, and cognition in healthy participants and patients with schizophrenia spectrum disorder
por: Scheurink, Toon Anton Willem, et al.
Publicado: (2023)

The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial
por: Brand, Bodyl A, et al.
Publicado: (2023)

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
por: Lähteenvuo, Markku, et al.
Publicado: (2020)

Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial
por: Aichholzer, Mareike, et al.
Publicado: (2022)

Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2022)

Twenty‐year medication use trends in first‐episode bipolar disorder
por: Poranen, Juulia, et al.
Publicado: (2022)

Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
por: Sommer, Iris E, et al.
Publicado: (2021)

Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders
por: Brand, Bodyl A., et al.
Publicado: (2023)

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
por: Taipale, Heidi, et al.
Publicado: (2014)

Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
por: Taipale, Heidi, et al.
Publicado: (2016)

Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
por: Heikkinen, Milja, et al.
Publicado: (2021)

Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
por: Heikkinen, Milja, et al.
Publicado: (2022)

Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
por: Heikkinen, Milja, et al.
Publicado: (2022)

Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder
por: Lieslehto, Johannes, et al.
Publicado: (2023)

Effects of Substance Use and Antisocial Personality on Neuroimaging-Based Machine Learning Prediction of Schizophrenia
por: Taipale, Matias, et al.
Publicado: (2023)

Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2018)

Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
por: Lintula, Eveliina, et al.
Publicado: (2019)

Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study
por: Paljärvi, Tapio, et al.
Publicado: (2023)

Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
por: Taipale, Heidi, et al.
Publicado: (2020)

Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2013)

From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
por: Tanskanen, Antti, et al.
Publicado: (2015)

From prescriptions to drug use periods - things to notice
por: Tanskanen, Antti, et al.
Publicado: (2014)

Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
por: Sarycheva, Tatyana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vg6njqbcin2diti74u3rlqh53j